ATAI (atai) Wutah bathi resik saben saham ing taun iki

Simbol resmi perusahaan atai.life (ATAI)

Low geopolitical pressure ensures stability for Atai Life Sciences N.V. (ATAI), as development is localized in the West. The annual EPS growth rate demonstrates profit dynamics, where 80.60 expresses the current value of the metric. Atai Life Sciences N.V. (ATAI) is developing therapies for treatment-resistant disorders, leveraging the neuropsychiatry market. The integration of digital solutions and psychedelics forms the foundation for treating severe depression.

ATAI (Atai Life Sciences N.V.) riwayat Wutah bathi saben saham ing taun lumaku saka 04.07.2022 nganti 26.09.2026

Rincian metrik komprehensif lan analitis Atai Life Sciences N.V. (ATAI)

Pambiji fundamental:Atai Life Sciences N.V.
Produk asil prodhuksi atai

For Atai Life Sciences N.V. (ATAI), success depends on the clinical trials of addiction treatments and the efficiency of R&D expenditures. The year-over-year EPS growth rate measures the pace of change in net income per share, reflecting the biotech's ability to transform scientific progress into financial results, which allows investors to compare the current turnaround in metrics with historical business development cycles.